JNJ-26489112
Identifiers
  • (S)-N-[(6-Chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC9H11ClN2O4S
Molar mass278.71 g·mol−1
3D model (JSmol)
  • NS(=O)(=O)NC[C@H]1COC2=C(O1)C=CC(Cl)=C2
  • InChI=1S/C9H11ClN2O4S/c10-6-1-2-8-9(3-6)15-5-7(16-8)4-12-17(11,13)14/h1-3,7,12H,4-5H2,(H2,11,13,14)/t7-/m0/s1
  • Key:KXSAIQPPGSSNKX-ZETCQYMHSA-N

JNJ-26489112 is an anticonvulsant drug being developed by Johnson & Johnson for the treatment of epilepsy.[1][2][3] JNJ-26489112 was designed as a successor to topiramate.[4] It is expected to have fewer side effects than topiramate because it lacks activity against carbonic anhydrase.[4]

JNJ-26489112 was studied as a treatment for major depressive disorder.[5] This clinical trial was terminated in 2013 due to a "sponsor portfolio decision", and no new development of JNJ-26489112 has been reported.

Its mechanism of action is unknown.[6]

See also

References

  1. ↑ Trenité DK, Diprospero NA, Moyer JA, Gambale J, Pandina G, Ford L, Girgis S, Xi L, Nye J (August 2013). "Evaluation of JNJ-26489112, a Novel Antiepileptic Drug: A Placebo-Controlled, Exploratory Study". Clinical Therapeutics. 35 (8): e70. doi:10.1016/j.clinthera.2013.07.204.
  2. ↑ Clinical trial number NCT00579384 for "A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram Response in Patients With Photosensitive Epilepsy" at ClinicalTrials.gov
  3. ↑ Di Prospero NA, Gambale JJ, Pandina G, Ford L, Girgis S, Moyer JA, et al. (May 2014). "Evaluation of JNJ-26489112 in patients with photosensitive epilepsy: a placebo-controlled, exploratory study". Epilepsy Research. 108 (4): 709–16. doi:10.1016/j.eplepsyres.2014.01.018. PMID 24560845. S2CID 25545178.
  4. 1 2 McComsey DF, Smith-Swintosky VL, Parker MH, Brenneman DE, Malatynska E, White HS, et al. (November 2013). "Novel, broad-spectrum anticonvulsants containing a sulfamide group: pharmacological properties of (S)-N-[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide (JNJ-26489112)". Journal of Medicinal Chemistry. 56 (22): 9019–30. doi:10.1021/jm400894u. PMC 4004761. PMID 24205976.
  5. ↑ Clinical trial number NCT01114698 for "A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder" at ClinicalTrials.gov
  6. ↑ Zaccara G, Schmidt D (February 2016). "Do traditional anti-seizure drugs have a future? A review of potential anti-seizure drugs in clinical development". Pharmacological Research. 104: 38–48. doi:10.1016/j.phrs.2015.12.011. PMID 26689774.

Further reading

  • Toxicological study of JNJ-26489112: Eichenbaum G, Zhou J, Kelley MF, Roosen W, Costa-Giomi P, Louden C, et al. (July 2014). "Implications of retinal effects observed in chronic toxicity studies on the clinical development of a CNS-active drug candidate". Regulatory Toxicology and Pharmacology. 69 (2): 187–200. doi:10.1016/j.yrtph.2014.03.005. PMID 24680767.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.